Billy Kenber is one of the most promising young journalists in the land, and he has, unsurprisingly, produced a compelling debut which surprises, entertains and inspires dismay. An essential read -- SATHNAM SANGHERA
Billy Kenber does a fantastic job, pulling apart the origins of the drugs industry and machinations of its shameless profiteers with surgical precision . . . it's quite a ride. A must-read for anyone who wants to understand how the drugs industry really does its business -- JACQUES PERETTI
Terrific reporting and a lucid and clear expose of how the drug industry too often puts profits ahead of patients -- GERALD POSNER
[Sick Money] distinguishes itself from many other books by its investigative power and meticulous clarity * * The Times * *
A forensic and very readable account of the reforms needed to make the pharmaceutical industry serve the public good as well as private profit . . . Kenber's ground-breaking investigative reporting has . . . resulted in a change in the law in the UK, intervention by regulators, cuts in the price of some medicines, life-changing benefits for patients, savings of hundreds of millions of pounds for the NHS and record fines for drug firms -- ANDREW GRICE
Powerful, gripping and rigorous, this book couldn't have come at a better time. Never has it been so important to delve into the tangled web behind the medicines and vaccines we all rely on. With years of research and reporting under his belt, Kenber is the perfect person to take us on this fascinating journey -- MAEVE McCLENAGHAN, author of NO FIXED ABODE
A clever exploration of a scandal that affects everyone who uses - and pays for - the NHS. This is an enormously complex subject, but Kenber finds the interesting characters and fascinating details that bring the story to life. A great and important read -- HOLLY WATT, author of CASEY BENEDICT series
A painstakingly researched and beautifully written history of the dark underbelly of the pharmaceutical industry, which never forgets to tell the stories of the vulnerable people harmed when these companies lose their moral compass. I could not put it down -- NIGEL PRAITIES, executive editor of the PHARMACEUTICAL JOURNAL
